Investigation of Vital Organ Specific Biomarkers Using Cell-Based Assays after Treatment with the Biofield Energy Treated Test Formulation

Journal: Cell & Cellular Life Sciences Journal PDF  

Published: 16-Jul-19 Volume: 4 Issue: 2

DOI: 10.23880/cclsj-16000144 ISSN: 2578-4811

Authors: Peoples JJ, Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M and Jana S

Citation: Peoples JJ, et al. Investigation of Vital Organ Specific Biomarkers Using Cell-Based Assays after Treatment with the Biofield Energy Treated Test Formulation. Cell Cellular Lif Sci J 2019, 4(2): 000145.

  • 17 Views
  • Downloads

Abstract

The present study aimed to determine the impact of the Biofield Energy Treated test formulation and different cell line mediums on vital organs function. Specific cell based assays were performed based on the vital organs function (bones, heart, liver, lungs, and brain). The test item (TI) and cell line media was divided into two parts; one was untreated (UTTI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, James Jeffrey Peoples, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell lines. Cytoprotective action of the test formulation showed a significant restoration of cell viability by 48.3% (at 25.5 μg/mL), 9.3% (at 1 μg/mL), and 64.1% (at 25.5 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 48.3% (at 25.5 μg/mL), 9.3% (at 1 μg/mL), and 64.1% (at 25.5 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cytoprotective activity in human hepatoma cells (HepG2) showed improved cell viability by 65.4% (at 1 μg/mL), 63.8% (at 1 μg/mL), and 39.4% (at 25.5 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinomic human alveolar basal epithelial cells (A549) showed improved cell viability by 28.4% (at 10 μg/mL), 101.7% (at 25.5 μg/mL), and 181.7% (at 0.1 μg/mL) in the UT-Med + BT-TI, BTMed + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 88.1% at 50 μg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 433.3% and 136.1% at 0.1 and 10 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 87.8% at 1 μg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 40.1% at 10 μg/mL, and improved cellular protection by 70.1% at 1 μg/mL in the BTMed + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.6% (at 10 μg/mL), 19% (at 10 μg/mL), and 61.2% (at 63.75 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 102.3% (at 1 μg/mL), 10.3% (at 25.5 μg/mL), and 38.4% (at 10 μg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 23.7% (at 0.1 μg/mL), 36.8% (at 25 μg/mL), and 51.9% (at 25 μg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 471% (at 10 μg/mL), 318.9% (at 10 μg/mL), and 326.2% (at 50 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

MTT assay showed that the test formulation was found safe and non-toxic against all the tested cell lines. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 48.3% (at 25.5 μg/mL), 9.3% (at 1 μg/mL), and 64.1% (at 25.5 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups respectively, as compared to the untreated test group, while in HepG2 cells the maximum restoration of cell viability by 65.4% (at 1 μg/mL), 63.8% (at 1 μg/mL), and 39.4% (at 25.5 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Similarly, the test formulation in A549 cells showed maximum restoration of cell viability by 28.4% (at 10 μg/mL), 101.7% (at 25.5 μg/mL), and 181.7% (at 0.1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells showed significantly increased ALP activity at 50 μg/mL by 84.5%, 87.8%, and 88.1% in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Similarly, ALP activity in Ishikawa cells with maximum cellular protection by 71.4% (at 0.1 μg/mL), 117.9% (at 10 μg/mL), and 433.3% (at 0.1 μg/mL) in the UT-Med + BTTI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. LDH activity was significantly decreased and the data was presented in terms of increased percentage cellular protection data, which showed maximum cellular protection by 87.8% (at 1 μg/mL), 40.1% (at 10 μg/mL), and 70.1% (at 1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALT activity was studied and data showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) by 35.6% (at 10 μg/mL), 19% (at 10 μg/mL), and 61.2% (at 63.75 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 102.3% (at 1 μg/mL), 10.3% (at 25.5 μg/mL), and 38.4% (at 10 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 23.7% (at 0.1 μg/mL), 36.8% (at 25 μg/mL), and 51.9% (at 25 μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 213.9%, 471%, and 283% in the UT-Med + BT-TI group at 1, 10, and 50 μg/mL respectively, while 318.9% and 212.5% increased RQ of VDR at 10 and 50 μg/mL respectively, in the BT-Med + UT-TI group, and increased RQ of VDR by 121%, 118.9%, and 326.2% at 1, 10, and 50 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test control group. Thus, Biofield Energy Treatment (The Trivedi Effect®) can be used for improving overall health such as significant role in cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune system related disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.